Can the NIH replace all private sector clinical R&D?

A paper by Proudman et al. (2024) finds that doing so would be extremely expensive. Including all preclinical, clinical and post-approval R&D activities, total annual costs to maintain the average lifecycle level of 49.4 approved drugs across all disease areas during the 2018–22 period was estimated to be $139.6 billion. Including only pre-launch costs, total…

Read More

State of Claims 2024: Insights from survey findings

Despite increased access to claims management technology, claims denials are still on the rise in 2024. Contributing factors include growing healthcare costs, stricter payer reimbursement policies, and claims processing errors. Providers are seeing an uptick in nonpayment, plus an added burden on administrative staff, disrupted patient care, and hits to the bottom line. Experian Health…

Read More